This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Journal: Brain Stimulation 4:266-74 (2011)
Authors: Y Levkovitz, A Sheer, E.V Harel, L.N Katz, D Most, A Zangen, M Isserles
Apathy is one hallmark of major depression (MDD). It is distinguished by lack of emotion, whereas other aspects of depression involve considerable emotional distress. Investigating both apathy and depression may increase the degree of treatment efficacy for both ailments together and apart.
Evaluate the differential effects of deep transcranial magnetic stimulation (dTMS) over the prefrontal cortex (PFC) on apathy and other aspects of depression in patients suffering from a depressive episode.
Fifty-four treatment-resistant MDD patients were evaluated with the Hamilton Rating Scale for Depression (HRSD), and then treated with dTMS. Apathy-related items from HRSD (ApHRSD) were compared with the remaining items from HRSD (DepHRSD). Antidepressant medications were withdrawn and active dTMS treatment was administered at 20 Hz, 5 days a week for 4 weeks. Changes in HRSD were recorded. Primary efficacy time point was 1 week after the end of active treatment.
At screening, ApHRSD distribution was unimodal (moderate apathy), with low correlation (r=0.17)between ApHRSD and DepHRSD. After treatment, a third had remitted apathy, and the correlation between ApHRSD and DepHRSD had dramatically increased (r=0.83). Severe ApHRSD (>7) at screening correlated with non-remission for both ApHRSD (R2=0.1993,P=.0012) and DepHRSD (R2=0.0860,P=.0334).
dTMS over the PFC improved both apathy and depression similarly. However, dTMS did not lead to MDD remission if ApHRSDat screening was >7 of 12. Further investigation using a larger sample will determine whether screening apathy at baseline could be used to predict efficacy of dTMS in MDD patients.